Therapeutic antibodies for human diseases at the dawn of the twenty-first century

被引:407
作者
Brekke, OH
Sandlie, I
机构
[1] Affitech AS, N-0349 Oslo, Norway
[2] Univ Oslo, Dept Biol, N-0349 Oslo, Norway
关键词
D O I
10.1038/nrd984
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Antibodies are highly specific, naturally evolved molecules that recognize and eliminate pathogenic and disease antigens. The past 30 years of antibody research have hinted at the promise of new versatile therapeutic agents to fight cancer, autoimmune diseases and infection. Technology development and the testing of new generations of antibody reagents have altered our view of how they might be used for prophylactic and therapeutic purposes. The therapeutic antibodies of today are genetically engineered molecules that are designed to ensure high specificity and functionality. Some antibodies are loaded with toxic modules, whereas others are designed to function naturally, depending on the therapeutic application. In this review, we discuss various aspects of antibodies that are relevant to their use as as therapeutic agents.
引用
收藏
页码:52 / 62
页数:11
相关论文
共 78 条
  • [41] HUMAN IMMUNE-RESPONSE TO MONOCLONAL-ANTIBODIES
    KHAZAELI, MB
    CONRY, RM
    LOBUGLIO, AF
    [J]. JOURNAL OF IMMUNOTHERAPY, 1994, 15 (01) : 42 - 52
  • [42] Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
    Kipriyanov, SM
    Moldenhauer, G
    Schuhmacher, J
    Cochlovius, B
    Von der Lieth, CW
    Matys, ER
    Little, M
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (01) : 41 - 56
  • [43] Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma
    Kipriyanov, SM
    Cochlovius, B
    Schäfer, HJ
    Moldenhauer, G
    Bähre, A
    Le Gall, F
    Knackmuss, S
    Little, M
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (01) : 137 - 144
  • [44] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY
    KOHLER, G
    MILSTEIN, C
    [J]. NATURE, 1975, 256 (5517) : 495 - 497
  • [45] Complement recruitment using bispecific diabodies
    Kontermann, RE
    Wing, MG
    Winter, G
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (07) : 629 - 631
  • [46] Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting
    Kortt, AA
    Dolezal, O
    Power, BE
    Hudson, PJ
    [J]. BIOMOLECULAR ENGINEERING, 2001, 18 (03): : 95 - 108
  • [47] LANG AB, 1993, J IMMUNOL, V151, P466
  • [48] Larrick J W, 1991, Hum Antibodies Hybridomas, V2, P172
  • [49] Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    Larson, RA
    Boogaerts, M
    Estey, E
    Karanes, C
    Stadtmauer, EA
    Sievers, EL
    Mineur, P
    Bennett, JM
    Berger, MS
    Eten, CB
    Munteanu, M
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    [J]. LEUKEMIA, 2002, 16 (09) : 1627 - 1636
  • [50] Treating human autoimmune disease by depleting B cells
    Looney, RJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) : 863 - 866